Combining Fluorescence and Magnetic Resonance Imaging in Drug Discovery-A Review

Area of Science:

• Biomedical imaging
• Drug discovery and development
• Nanotechnology

Background:

• Multimodal imaging, integrating fluorescence and MRI, is crucial for modern pharmacokinetics.
• Fluorescence offers high molecular sensitivity for real-time cellular process monitoring.
• MRI provides non-invasive anatomical visualization without ionizing radiation.

Purpose of the Study:

• To explore the role and potential of fluorescence-MRI hybrid imaging in accelerating preclinical drug evaluation.
• To highlight the integration of molecular and anatomical data acquisition for improved therapeutic design.
• To discuss the applications and challenges of multimodal imaging in oncology, neurology, and cardiology.

Main Methods:

• Development and application of hybrid probes, such as SPIONs with NIR fluorophores or gadolinium complexes with optical dyes.
• Simultaneous acquisition of molecular (fluorescence) and anatomical (MRI) data.
• Exploration of applications in oncology, neurology, and cardiology for visualizing pathologies.

Main Results:

• Hybrid probes enable simultaneous molecular and anatomical data acquisition in a single examination.
• Multimodal systems show promise in visualizing tumor biology, amyloid pathology, and vascular inflammation.
• Identified challenges include potential toxicity, limited fluorescence penetration, probe stability, and synthesis complexity.

Conclusions:

• Fluorescence-MRI hybrid imaging holds significant promise for enhancing pharmacokinetic and pharmacodynamic studies.
• Advances in nanotechnology (biodegradable carriers, Mn-based contrasts) and AI are overcoming current limitations.
• Future applications in personalized medicine aim for precise therapy planning and reduced clinical failure rates.